Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12

HOS-134486 · Präparat HOS-097580

Saquinavir: comparison of saquinavir/ritonavir 1,000/100 mg twice daily vs. saquinavir/darunavir/ritonavir 1,000/400/100 mg twice daily. Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily. HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir† Lopinavir/ritonavir 400/100 lopinavir AUC ↑ 9% Due to a decrease in the exposure mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%, lopinavir Cmax ↓ 2% appropriate doses of the combination have not been darunavir AUC ↓ 38% ‡ established. Hence, concomitant use darunavir Cmin ↓ 51%‡ of darunavir co-administered with darunavir Cmax ↓ 21%‡ low dose ritonavir and the Lopinavir/ritonavir lopinavir AUC ↔ combination product 533/133.3 mg twice daily lopinavir Cmin ↑ 13% lopinavir/ritonavir is lopinavir Cmax ↑ 11% contraindicated (see section 4.3). darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% ‡ based upon non dose normalised values CCR5 ANTAGONIST Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150 mg twice daily maraviroc Cmin ND 150 mg twice daily when co- maraviroc Cmax ↑ 129% administered with darunavir with darunavir, ritonavir concentrations low dose ritonavir. were consistent with historical data α1-ADRENORECEPTOR ANTAGONIST

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) protease (HOS-085623) saquinavir (HOS-084522) maraviroc (HOS-086186) ritonavir (HOS-084521)